Skip to main contentSkip to navigationSkip to search
SEK  %

ColdZyme demonstrates reduced sick leave during cold season

Enzymatica presents results recently published in Open Journal of Respiratory Diseases (OJRD)[1], Enzy-003, an open label evaluation by elderly care personnelatEksjö Municipality, investigating the impact of ColdZyme on sick leave during the cold season. ENZY-003 demonstrated a substantial reduction in individual average sick leave days, reduced from 5.2 to 3.7 days among 74 employees at an elderly care residence using ColdZyme during the cold season, compared to the previous year. In addition, 63 percent of those who caught colds reported that their symptoms were milder while using ColdZyme in comparison to previous colds. This result is encouraging and shows the potential to reduce sick-leave days by using ColdZyme in the workplace.

The Enzy-003 study, carried out at a Swedish elderly care housing at Eksjö Municipality, compared the sick leave frequency among 111 employees during a five-month period of ColdZyme treatment, with that registered during the same period the previous year. 24 subjects were excluded in the analysis due to having long-term sickness, not attributed to the common cold (>29 days’ sick leave in 5 months). A substantial reduction of number of sick-leave days was observed among the remaining 74 subjects, with individual average sick leave days reduced from 5.2 to 3.7 days, (p=0.05)[2] and total sick leave days decreasing from 392 without, to 279 with ColdZyme.According to the study results, 63 percent of the staff reported that their symptoms were milder while using ColdZyme in comparison to previous infections.

“Although upper respiratory tract infections can hardly be considered a severe illness, colds pose a major economic burden for both society and the individual. The health economic consequences are considerable for sickness absences both in elderly care and in other public services,” says Christina Bråkenhielm Persson, Healthcare Director at Eksjö Municipality.

Fredrik Lindberg, CEO of Enzymatica commented:” We are satisfied with the positive outcome of ENZY-003, which is a study that reflects a real life situation during winter season”.

The current study supports the results of a previous cold study – COLDPREV – indicating that ColdZyme can reduce the number of sick days.

ColdZyme, being one of the few treatments that addresses the source of common cold by protecting the throat from virus attachment, has in a few years established itself as one of the best-selling common cold products in Swedish pharmacies.

Today the product is marketed and sold in Sweden, Denmark, Norway, Finland, Iceland, UK and Spain. The company is in negotiations with a number of potential distributor for the launch of ColdZyme in other markets. In the beginning of November Enzymatica signed an exclusive distribution agreement with Endeavour Consumer Health for Australia and New Zealand for marketing and sales of ColdZyme.

[1] Clarsund et al, Evaluation of ColdZyme Mouth Spray against Common Cold in Elderly Care Personnel, Open Journal of Respiratory Diseases, 2017, 7, 12-1

[2] p-value, statistical significance value

For more information, contact

Fredrik Lindberg, CEO, Enzymatica AB Tel: +46 708-86 53 70 | Email:

About Enzymatica AB

Enzymatica AB is a life sciences company that develops and sells medical devices for fighting infectious diseases. In a short period of time, the company developed ColdZyme®, a unique mouth spray for fighting colds, launched the product in seven markets and established it as one of the best-selling cold products in Swedish pharmacies measured in SEK. Our strategy is to continue growing by strengthening our position on existing markets and expanding to more geographic markets via established partners. The company’s head office is in Lund and it is listed on the Nasdaq First North. For more information, please go to: